ArticlePloS one

The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.

Georgios Tsivgoulis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.